Keith R Leonard
CIK 1416180 · Chief Executive Officer · last filed 2026-06-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.12M
Companies
8
Total Filings
105
Lifetime Open-Market Net
-$13.87M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ARQT | Director | 29,651 | $25.92 | $768.6K | -$997.2K | 8 | 2026-06-09 |
| ISRG | Director | 901 | $393.38 | $354.4K | -$2.78M | 25 | 2026-04-30 |
| Unity Biotechnology, Inc. (UBX) Delisted | Director | 58,955 | $0.20 | $11.8K | $0 | 11 | 2024-06-21 |
| Sienna Biopharmaceuticals, Inc. (SNNA) Delisted | Director | 131,784 | — | — | $500.5K | 5 | 2019-06-03 |
| Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Director | 0 | $10.19 | $0 | -$897.3K | 3 | 2016-06-24 |
| KYTHERA BIOPHARMACEUTICALS INC (KYTH) Delisted | President & CEO | 763,076 | — | — | -$9.70M | 43 | 2015-10-02 |
| AFFYMAX INC (AFFY) Delisted | Director | — | — | — | $0 | 6 | 2012-06-18 |
| ARYx Therapeutics, Inc. (ARYX) Delisted | Director | — | — | — | $0 | 3 | 2010-05-03 |
Recent Filings · Page 3 of 11
105 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-05-02 | ISRG | Grant (A) | — | $0 | EDGAR |
| 2022-04-26 | ISRG | Exer (M) | +555 | $0 | EDGAR |
| 2021-09-07 | ARQT | Grant (A) | — | $0 | EDGAR |
| 2021-08-03 | ISRG | Mixed | — | -$535.1K | EDGAR |
| 2021-06-28 | Unity Biotechnology, Inc. (UBX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-04-26 | ISRG | Mixed | +255 | $0 | EDGAR |
| 2020-06-24 | Unity Biotechnology, Inc. (UBX) Delisted | Tax (F) | −4,711 | -$45.6K | EDGAR |
| 2020-06-22 | Unity Biotechnology, Inc. (UBX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-04-27 | ISRG | Mixed | +262 | $0 | EDGAR |
| 2020-02-13 | ISRG | Mixed | — | -$507.6K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.